Actively Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Led by Vega Therapeutics, Inc · Updated on 2026-04-03
60
Participants Needed
14
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
CONDITIONS
Official Title
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 12 and 75 years, inclusive
- No clinically significant abnormal results in laboratory tests, ECG, or vital signs
- Documented diagnosis of von Willebrand Disease of any type
- Historical annualized bleeding rate of 12 or more bleeds per year, excluding menstrual and under the skin bleeds
- Considered by the investigator suitable for routine prophylaxis to reduce bleeding episodes
- Hemoglobin level of at least 8 g/dL and platelet count of at least 100 x 10^9/L at screening
You will not qualify if you...
- Use of routine prophylaxis with von Willebrand factor-containing concentrates at least once per week during the past 6 months before screening
- Planning to start routine prophylaxis with von Willebrand factor-containing concentrates or any other hemostatic treatment during the study
- Presence of pro-thrombotic disorders or abnormal thrombophilia lab results
- History of arterial or venous thrombosis, including superficial thrombophlebitis or embolism
- Evidence of renal, liver, nervous system, respiratory, cardiovascular, cerebrovascular, peripheral vascular, or metabolic disease
- Baseline factor VIII activity above the lower limit of normal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
Actively Recruiting
2
Luskin Orthopaedic Institute For Children
Los Angeles, California, United States, 90007
Actively Recruiting
3
UC Davis Medical Center
Sacramento, California, United States, 95817
Actively Recruiting
4
University of California San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
5
Emory University Hospital
Atlanta, Georgia, United States, 30308
Actively Recruiting
6
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30329
Actively Recruiting
7
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
8
Science 37, Inc. (Virtual Clinical MetaSite)
Morrisville, North Carolina, United States, 27560
Actively Recruiting
9
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
10
UT Southwestern Children's Hospital
Dallas, Texas, United States, 75235
Actively Recruiting
11
Washington Center for Bleeding Disorders
Seattle, Washington, United States, 98101
Actively Recruiting
12
K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)
Tbilisi, Georgia, 0159
Actively Recruiting
13
Frankfurt University Hospital (Universitätsmedizin Frankfurt)
Frankfurt, Germany, 60596
Actively Recruiting
14
Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist
Johannesburg, South Africa, 2194
Actively Recruiting
Research Team
C
Clinical Trials- Vega Therapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here